Isabel Paiva

Isabel Paiva

Auto-generated profile, based on publicly available information

Isabel Paiva

Laboratoire de Neurosciences Cognitives et Adaptatives (LNCA), UMR 7364, Université de Strasbourg-CNRS, Strasbourg, France

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2022 in Science
Verified
Journal Article
Closed access
MMMaria Manfredi-Lozano
Maria Manfredi-Lozano
VLValerie Leysen
Valerie Leysen
MAMichela Adamo
Michela Adamo
IPIsabel Paiva
Isabel Paiva
RRRENAUD ROVERA
RENAUD ROVERA
VPVincent Prévot
Vincent Prévot
At the present time, no viable treatment exists for cognitive and olfactory deficits in Down syndrome (DS). We show in a DS model (Ts65Dn mice) that these progressive nonreproductive neurological symptoms closely parallel a postpubertal decrease in hypothalamic as well as extrahypothalamic expression of a master molecule that controls reproduction—gonadotropin-releasing hormone (GnRH)—and appear related to an imbalance in a microRNA-gene network known to regulate GnRH neuron maturation together with altered hippocampal synaptic transmission. Epigenetic, cellular, chemogenetic, and pharmacological interventions that restore physiological GnRH levels abolish olfactory and cognitive defects in Ts65Dn mice, whereas pulsatile GnRH therapy improves cognition and brain connectivity in adult DS patients. GnRH thus plays a crucial role in olfaction and cognition, and pulsatile GnRH therapy holds promise to improve cognitive deficits in DS.

1 February 2021 in European Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
JCJoakim Crona
Joakim Crona
EBEric Baudin
Eric Baudin
Massimo TerzoloMassimo Terzolo
Massimo Terzolo
ACALEXANDRA CHRISOULIDOU
ALEXANDRA CHRISOULIDOU
AAAnna Angelousi
Anna Angelousi
FBFelix Beuschlein
Felix Beuschlein
Adrenocortical carcinoma (ACC) is an orphan disease lacking effective systemic treatment options. The low incidence of the disease and high cost of clinical trials are major obstacles in the search for improved treatment strategies. As a novel approach, registry-based clinical trials have been introduced in clinical research, so allowing for significant cost reduction, but without compromising scientific benefit. Herein, we describe how the European Network for the Study of Adrenal Tumours (ENSAT) could transform its current registry into one fit for a clinical trial infrastructure. The rationale to perform randomized registry-based trials in ACC is outlined including an analysis of relevant limitations and challenges. We summarize a survey on this concept among ENSAT members who expressed a strong interest in the concept and rated its scientific potential as high. Legal aspects, including ethical approval of registry-based randomization were identified as potential obstacles. Finally, we describe three potential randomized registry-based clinical trials in an adjuvant setting and for advanced disease with a high potential to be executed within the framework of an advanced ENSAT registry. Thus we, therefore, provide the basis for future registry-based trials for ACC patients. This could ultimately provide proof-of-principle of how to perform more effective randomized trials for an orphan disease.

1 May 2021 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
DSDiana Festas da Silva
Diana Festas da Silva
ALAdriana De Sousa Lages
Adriana De Sousa Lages
JCJoana Serra Caetano
Joana Serra Caetano
RCRita Cardoso
Rita Cardoso
IDIsabel Dinis
Isabel Dinis
AMAlice Mirante
Alice Mirante
Introduction: Hypoparathyroidism is characterized by low or inappropriately normal PTH production, hypocalcemia and hyperphosphatemia. Autosomal dominant hypocalcemia (ADH) type 1 is one of the genetic etiologies of this, caused by heterozygous activating mutations in the CASR gene. Some individuals fail to meet treatment goals despite standard therapy. Clinical Case: A 13-year-old male patient was admitted in the emergency department due to syncope during physical activity. There was no reference to seizures or other complaints. Standard screening for metabolic diseases revealed no changes at the 7th day of life and family history was unremarkable. There was a history of febrile seizures up to 5 years of age with several hospitalizations for diagnosis investigation that were inconclusive. Physical examination showed a positive Chvostek signal, without other changes. A basic workup revealed hypocalcemia 1.67mmol/L (NR: 2.19-2.66), hyperphosphatemia 3.06mmol/L (NR: 0.95-1.75), hypomagnesemia 0.62mmol/L (NR: 0.7-1.0), low 25Hydroxyvitamin D 8.7ng/mL (NR: >30ng/mL) and inappropriately low PTH 4.0pg/mL (NR: 16.0-87.0). Cranial computed tomography scan showed bilateral calcifications of the basal ganglia. Dual-energy x-ray absorptiometry revealed bone mineral density z-scores increased 15% in spine lumbar and decreased 7% in left femur. Cardiac ultrasound and electrocardiography were normal. The patient started therapy with intravenous calcium gluconate. During this treatment, he developed significant calcification of the peripheral veins at the site of administration, leading to intravenous therapy suspension. The dose of oral calcium, calcitriol and magnesium was gradually increased and sevelamer started to control hyperphosphatemia. Despite the optimization, the patient maintained hypocalcemia refractory to standard therapy. As a last resource strategy in therapeutic optimization, the patient started on rhPTH (1-34). Ever since, the patient has been clinically asymptomatic with biochemical stability and with a reasonable quality of life. At age 18, renal ultrasound revealed diffuse medullary nephrocalcinosis. The genetic testing revealed a novel variant c.368T>C p.(Leu123Ser) likely pathogenic in heterozygosity in the CASR gene, suggesting the diagnosis of ADH type 1. The patient′s mother did not give her consent for genetic study and patient’s father had already died with a diagnosis of acute leukemia. Conclusion: This case can be explained by the presence of a likely pathogenic variant in heterozygosity in the CASR gene that has been described in the medical literature that has not been identified in gnomAD population database, suggesting the diagnosis of ADH type 1. rhPTH (1-34) may be a treatment option for those individuals who are not well controlled on standard therapy, but long-term follow-up studies are needed to reinforce its safety.

1 April 2013 in Endocrine Abstracts
Verified
Journal Article
Closed access
JSJoana Saraiva
Joana Saraiva
IPIsabel Paiva
Isabel Paiva
MAMarcia Alves
Marcia Alves
SBSofia Barbosa-Gouveia
Sofia Barbosa-Gouveia
CMCarolina Moreno
Carolina Moreno
FCFrancisco Carrilho
Francisco Carrilho
Introduction: Cushing’s disease (CD) is a Grave disease that requires a multidisciplinary and individualized treatment approach. Case report: We describe the case of a 31-years old female patient with Cushing disease diagnosed in 2007. She initially complained of weight fluctuations, amenorrheia, rounded face with plethora and acne, for 1 year duration. Analytically: 0800 h plasma cortisol of 14 μg/dl (5–25) and 2300 h 15 μg/dl, ACTH 18 and 20 pg/ml, respectively; UFC 420–510 μg/24 h (10–80). Cortisol after LD-DST 3.4 μg/dl and after 2 days LD-DST 13 μg/dl. CRH test: plasma cortisol increased 20% and ACTH 60%. MRI: 5 mm lesion in pituitary left lobe. She was submitted to transphenoidal surgery (TSS) in 2/2008. Pathology: corticotrophinoma. After surgery: 0800 h plasma cortisol 9.4 μg/dl and 2300 h 4.1 μg/dl, ACTH 17 pg/ml and 15 pg/dl; UFC 86 μ/24 h; 2 days LD-DST cortisol<0.1 μg/dl. No residue in MRI. Follow-up until 11/2009 revealed fluctuating clinical symptoms with periods of depression, acne and weight gain. She also had osteoporosis and renal calculi. UFC: 45, 135, 85, 166 and 210 μg/24 h. Plasma cortisol after 2 day LD-DST: 6.6 μg/dl. MRI: possible small lesion, not confirmed in MRI of 3/2010. Nevertheless, in 4/2010 she was submitted to a second TSS, without any corticotrophinoma found. Hormonal evaluation (5/2010): plasma cortisol after 2 days LD-DST of 4.0 μg/dl, UFC 146–275 μg/24 h, no pituitary insufficiencies. Inferior petrosal sinus sampling study wasn’t conclusive. MRI (11/2011) wasn’t suggestive of microadenoma. Since then and until 8/2012, worsening of clinical manifestations: menstrual irregularities, acne, depression, supraclavicular fullness, body bruising and osteoporosis. UFC 330 μg/24 h, 0800 h plasma cortisol 15 μg/dl and ACTH 26 pg/dl. Abdominal CT (7/2012): adrenal glands without alterations. As she maintains active disease bilateral adrenalectomy was proposed, to preserve fertility. Conclusions: CD remains a challenge at diagnosis and causal treatment. Simultaneously is associated with severe morbidity (and mortality) related with the severity but also with the duration of the hypercortisolism. For young patients preservation of gonadal function is an important issue, leading to the sooner option for bilateral adrenalectomy.

3 May 2017 in Endocrine Abstracts
Verified
Journal Article
Closed access
ALAdriana De Sousa Lages
Adriana De Sousa Lages
IPIsabel Paiva
Isabel Paiva
LGLeonor Gomes
Leonor Gomes
POPatricia Oliveira
Patricia Oliveira
FBFrancisco Belo
Francisco Belo
FCFrancisco Carrilho
Francisco Carrilho
Background: Pituitary adenomas (PA) are common intracranial tumors that are mainly considered benign. A small group of patients exhibit clinically aggressive behavior sometimes unrelated to the histopathological or radiological features. Methods: Twelve patients were selected harboring a PA with clinical features of aggressiveness. All the patients underwent pre and postoperative endocrinologic/neuroradiologic evaluation. Results: 10/12 patients were male, mean age at diagnosis 38.1 years (range 12–58) and mean follow-up 14.3 years (range 5–28; died 3/12). In 9/12 cases, the first manifestation was visual impairment (visual field loss, reduction in visual acuity and/or cranial nerve palsies). All the patients had invasive pituitary macroadenomas with expansion into surrounding anatomical structures (11 cavernous sinus; 7 sphenoid sinus; 7 bone invasion). The 12 patients underwent a total of 52 surgical procedures (median 4; range 3–6). Apparently total removal was achieved in 8/12 patients at the first surgical procedure. Regarding histological subtype: 5 gonadotrophinomas; 2 null-cell adenomas; 2 corticotrophinomas; 1 thyrotrophinoma; 1 prolactinoma and 1 plurihormonal adenoma (GH/ACTH). Proliferation markers as ki67 >3% was identified in 4; >2mitoses/10 HPF in 3 and p53 IHC expression in 4/12 cases. Six patients underwent radiation therapy (RT) postoperatively (5 conventional external RT; 1 stereotactic radiosurgery). Medical therapy was tried in 4/12 patients: 3 with dopamine agonists; 1 with somatostatin analog (pasireotide); 2 with steroidogenesis inhibitors (ketoconazole and metyrapone). Possible metastatic pulmonary disease was identified only in one case; the patient died of tumor progression 10-years after the diagnosis. Conclusion: Aggressive pituitary tumors constitute a challenging but not completely defined entity. We found an elevated number of surgical procedures by patient and smaller proportion of RT/medical treated patients compared with literature, however, with similar outcomes. Adverse results in treatment are possibly related to difficulty in early detection of this patients’ subgroup that must be treated with a multimodal approach.

21 August 2020 in Endocrine Abstracts
Verified
Journal Article
Closed access
DCDiana Catarino
Diana Catarino
Diana C. Silva PereiraDiana C. Silva Pereira
Diana C. Silva Pereira
JGJoana Guiomar
Joana Guiomar
CMCarolina Moreno
Carolina Moreno
CRCritina Ribeiro
Critina Ribeiro
IPIsabel Paiva
Isabel Paiva
Introduction: Adrenocortical carcinoma is a rare endocrine disease characterized by an aggressive behaviour with a poor prognosis. Clinical experience, even with a little number of patients, has enhanced knowledge about this malignancy, in most cases challenging. Objective: Characterization of patients with adrenocortical carcinoma followed at the endocrine department of a hospital centre, between 1991 and 2019. Methods: Retrospective cohort study, based on clinical records of patients with histopathologic confirmed result of adrenocortical carcinoma. Statistical analyses with SPSS v.25. Results and conclusion: We obtained 34 patients: 79.4% female, mean age at the diagnosis 50.03 ± 13.02 years. Clinical presentation: 50% (n = 17) - symptoms of adrenal hormone excess, 32% (n = 11) - low back/abdominal pain or weight loss, 18% (n = 6) - adrenal incidentalomas. Computerized tomography scan (CT) data: mean tumour size - 10.5 ± 4.2 cm, necrosis imaging- 80%, CT density >10UH - 100%, additional invaded organs – 35.3% (mainly kidney and inferior cava vein), metastases at the diagnosis – 26.5%. Laboratory analysis: functional tumours (71%, n = 24); hypercortisolism – n = 11; hypercortisolism and androgen excess – n = 9; androgen excess – n = 3, hypercortisolism, androgen and mineralocorticoid excess – n = 1. Surgery treatment was performed on 88.2% (n = 30) of patients. Surgical approach: open surgery – 67% (n = 20), laparoscopic adrenalectomy – 32% (n = 10). Resection: R0 – 72.4%, R1 – 24.1%, R2 – 4.4%. ENSAT stage: 66.7% (n = 20) in the stage II, 20% (n = 6) in stage III, 13.3% (n = 4) in stage IV. Histopathologic analysis: median of weight tumour – 260.5 g(680 g), between 71-2600 g; mean Weiss-score −5.36 ± 1,55; mitotic rate (>5 per 50 high-power fields) – 73.3%, abnormal mitoses – 68.4%, -cytoplasm with clear cells comprising 25% or less of the tumour – 84.6%, necrosis – 91.7%, capsular invasion – 62.5%, mean Ki-67 index −26.2 ± 22.8. Medical adjuvant therapy was performed on 70.6% (n = 4) patients: mitotane monotherapy (n = 12), mitotane and chemotherapy (n = 5), mitotane and metyrapone (n = 5), mitotane, chemotherapy and metyrapone (n = 2). Radiotherapy was performed only on one patient. Relative to mitotane therapy: median initial dose −1.5 g/day (1.5), median of maximum dose −5.4 g/day (3.0); mean of mitotane plasma level −14.8 ± 7.9 mg/l. Therapeutic mitotane plasma level was reached at 60% of patients. The mean overall survival was 52.2 ± 79.1 months and was higher in youngers patients (r = -0.09; P = 0.596). Actually, 12 patients are alive, 11 of them with complete remission. Despite the poor prognosis of this malignancy, the high survival rate and the high number of patients on complete remission found in this series (32.4%) is highlighted.